Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice.

Literature DB >> 25257990

The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice.

T R Rosean¹, V S Tompkins², A K Olivier², R Sompallae³, L A Norian⁴, H C Morse⁵, T J Waldschmidt⁶, S Janz⁶.

Abstract

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：
Interleukin-6

Year: 2014 PMID： 25257990 PMCID： PMC4286499 DOI： 10.1038/leu.2014.260

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

× No keyword cloud information.

15 in total

1. Preventive strategies in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Authors: S Vincent Rajkumar
Journal: Am J Hematol Date: 2012-04-10 Impact factor: 10.047

2. IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia.

Authors: Lucy S Hodge; Steve C Ziesmer; Zhi Zhang Yang; Frank J Secreto; Morie A Gertz; Anne J Novak; Stephen M Ansell
Journal: Blood Date: 2012-09-13 Impact factor: 22.113

3. Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma.

Authors: Ajai Chari; Hadass Pri-Chen; Sundar Jagannath
Journal: Clin Lymphoma Myeloma Leuk Date: 2013-01-10

4. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.

Authors: B Klein; X G Zhang; M Jourdan; J Content; F Houssiau; L Aarden; M Piechaczyk; R Bataille
Journal: Blood Date: 1989-02 Impact factor: 22.113

5. Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice.

Authors: Sung Sup Park; Arthur L Shaffer; Joong Su Kim; Wendy duBois; Michael Potter; Louis M Staudt; Siegfried Janz
Journal: Cancer Res Date: 2005-09-01 Impact factor: 12.701

Review 6. Pathogenesis of myeloma.

Authors: Kenneth C Anderson; Ruben D Carrasco
Journal: Annu Rev Pathol Date: 2011 Impact factor: 23.472

7. Elevation of interleukin-6 in response to a chronic inflammatory stimulus in mice: inhibition by indomethacin.

Authors: E Shacter; G K Arzadon; J Williams
Journal: Blood Date: 1992-07-01 Impact factor: 22.113

8. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.

Authors: G Lattanzio; C Libert; M Aquilina; M Cappelletti; G Ciliberto; P Musiani; V Poli
Journal: Am J Pathol Date: 1997-09 Impact factor: 4.307

9. Distinct tumorigenic potential of abl and raf in B cell neoplasia: abl activates the IL-6 signaling pathway.

Authors: D M Hilbert; T S Migone; M Kopf; W J Leonard; S Rudikoff
Journal: Immunity Date: 1996-07 Impact factor: 31.745

10. A monoclonal gammopathy precedes multiple myeloma in most patients.

Authors: Brendan M Weiss; Jude Abadie; Pramvir Verma; Robin S Howard; W Michael Kuehl
Journal: Blood Date: 2009-02-20 Impact factor: 22.113

11 in total

1. Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow.

Authors: T Matthes; B Manfroi; A Zeller; I Dunand-Sauthier; B Bogen; B Huard
Journal: Leukemia Date: 2015-06-19 Impact factor: 11.528

2. TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.

Authors: E Nievergall; J Reynolds; C H Kok; D B Watkins; M Biondo; S J Busfield; G Vairo; K Fuller; W N Erber; T Sadras; R Grose; D T Yeung; A F Lopez; D K Hiwase; T P Hughes; D L White
Journal: Leukemia Date: 2016-02-22 Impact factor: 11.528

3. Adoptive B-cell transfer mouse model of human myeloma.

Authors: V S Tompkins; T R Rosean; C J Holman; C DeHoedt; A K Olivier; K M Duncan; X Jing; S D Foor; M R Acevedo; S A Walsh; G Tricot; F Zhan; S Janz
Journal: Leukemia Date: 2015-07-23 Impact factor: 11.528

4. IL-6 augments IL-4-induced polarization of primary human macrophages through synergy of STAT3, STAT6 and BATF transcription factors.

Authors: Sahil Gupta; Arpit Jain; Shahzad Nawaz Syed; Ryan G Snodgrass; Beatrice Pflüger-Müller; Matthias S Leisegang; Andreas Weigert; Ralf P Brandes; Ingo Ebersberger; Bernhard Brüne; Dmitry Namgaladze
Journal: Oncoimmunology Date: 2018-07-30 Impact factor: 8.110

5. The adaptor protein TRAF3 inhibits interleukin-6 receptor signaling in B cells to limit plasma cell development.

Authors: Wai W Lin; Zuoan Yi; Laura L Stunz; Christian J Maine; Linda A Sherman; Gail A Bishop
Journal: Sci Signal Date: 2015-09-01 Impact factor: 8.192

6. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.

Authors: Koji Matsuo; Kosei Hasegawa; Kiyoshi Yoshino; Ryusuke Murakami; Takeshi Hisamatsu; Rebecca L Stone; Rebecca A Previs; Jean M Hansen; Yuji Ikeda; Akiko Miyara; Kosuke Hiramatsu; Takayuki Enomoto; Keiichi Fujiwara; Noriomi Matsumura; Ikuo Konishi; Lynda D Roman; Hani Gabra; Christina Fotopoulou; Anil K Sood
Journal: Eur J Cancer Date: 2015-07-31 Impact factor: 9.162